Innovation
Innovation
Improving Health for All
We develop new ways to promote faster development of valuable treatments and ensure diverse patient groups can access them.
Featured White Paper
The Elasticity of Pharmaceutical Innovation: How Much Does Revenue Drive New Drug Development?
For every 10% reduction in expected revenues, we can expect 2.5% to 15% less pharmaceutical innovation. Policymakers should take care to balance reductions in health outcomes long-term with short-term access improvements.
Experts: Karen Van Nuys, Darius Lakdawalla, Dana Goldman
Top Innovation Stories View All
Journal Article
Beyond the QALY: Putting Preferences to the Test in Health Technology Assessment
Featured Experts: Darius Lakdawalla, Alice Chen, Jason Doctor, Dana Goldman, Barry Liden, Karen Mulligan, Desi Peneva, Charles E. Phelps
In The News View All
STAT News
Kanter’s research finds patient reps on FDA advisory committees often have ties to pharma-funded groups
Featured Experts: Genevieve P. Kanter
Endpoints
Schaeffer experts recommend FDA update guidance on early-stage clinical research
Featured Experts: Lowell Schiller, Barry Liden
PharmaVoice
Kanter discusses the risks of a prolonged FDA commissioner vacancy
Featured Experts: Genevieve P. Kanter
Endpoints
Schiller says the FDA is showing signs of renewed predictability after the commissioner’s departure
Featured Experts: Lowell Schiller
STAT News
Schiller urges FDA to establish formal procedures for commissioner’s voucher program
Featured Experts: Lowell Schiller
Related Subtopics
High drug prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. We connect industry, academia and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Team View All Innovation Experts
